Back to News
Market Impact: 0.25
InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million
Source: GlobeNewswire
Healthcare & BiotechProduct LaunchesCorporate Guidance & Outlook
The company amended existing warrants to align their trigger event with anticipated FDA approval of its CGuard Prime 80 cm device. Management continues to expect approval in Q4 2026, creating a potentially positive regulatory catalyst, though approval remains prospective.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- Tech stock rout, driven by US AI fears, continues in Asian trading
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- RIP the Cybertruck: Elon Musk says Tesla will wind down production of its most polarizing EV
- Tesla will stop making the Cybertruck in 2027
- Tesla is 'winding down' Cybertruck production at its Texas Gigafactory
- Tesla is ‘winding down’ production of the Cybertruck next year